Older Idiopathic Pulmonary Fibrosis Male Patients Are at a Higher Risk of Nintedanib Dose Reduction.
Body mass index
Idiopathic pulmonary fibrosis
Nintedanib
Therapy
Journal
Respiration; international review of thoracic diseases
ISSN: 1423-0356
Titre abrégé: Respiration
Pays: Switzerland
ID NLM: 0137356
Informations de publication
Date de publication:
Historique:
received:
09
05
2020
accepted:
14
05
2020
pubmed:
28
8
2020
medline:
3
9
2021
entrez:
28
8
2020
Statut:
ppublish
Résumé
Two pharmaceutical agents have been approved for treatment of idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. We investigated the need of dose reduction in consecutive patients treated with nintedanib in relation to gender and body max index, comparing the population over and under 80 years of age. We retrospectively reviewed the data of all consecutive IPF patients treated with nintedanib for at least 3 months. Data on age, gender, body max index, side effects, and duration of therapy after enrolment were recorded. A total of 82 patients has been evaluated. All dose reductions were related to side effects and/or toxicities. The need for a dose reduction was significantly more frequent in patients aged 80 years or older (50 vs. 26.8%, p = 0.039), independently from their body mass index. A total of 52% of males >80 years and only 16% of males <80 years reduced the dose (p = 0.002). Male gender and not body mass index in IPF patients aged ≥80 years treated with nintedanib seems to influence dose reduction.
Sections du résumé
BACKGROUND
BACKGROUND
Two pharmaceutical agents have been approved for treatment of idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib.
OBJECTIVES
OBJECTIVE
We investigated the need of dose reduction in consecutive patients treated with nintedanib in relation to gender and body max index, comparing the population over and under 80 years of age.
METHODS
METHODS
We retrospectively reviewed the data of all consecutive IPF patients treated with nintedanib for at least 3 months. Data on age, gender, body max index, side effects, and duration of therapy after enrolment were recorded.
RESULTS
RESULTS
A total of 82 patients has been evaluated. All dose reductions were related to side effects and/or toxicities. The need for a dose reduction was significantly more frequent in patients aged 80 years or older (50 vs. 26.8%, p = 0.039), independently from their body mass index. A total of 52% of males >80 years and only 16% of males <80 years reduced the dose (p = 0.002).
CONCLUSIONS
CONCLUSIONS
Male gender and not body mass index in IPF patients aged ≥80 years treated with nintedanib seems to influence dose reduction.
Identifiants
pubmed: 32854107
pii: 000508667
doi: 10.1159/000508667
doi:
Substances chimiques
Indoles
0
Protein Kinase Inhibitors
0
nintedanib
G6HRD2P839
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
646-648Informations de copyright
© 2020 S. Karger AG, Basel.